**HPV MODULE**

**RESOURCES**

**Publications**

1.  American Cancer Society. Cancer facts and figures 2003. Available
    from URL:
    <http://www.cancer.org/downloads/STT/CAFF2003PWSecured.pdf>.

2.  Baldwin SB, Wallace DR, Papenfuss MR, Abrahamsen M, Vaught LC,
    Kornegay JR, et al. Human papillomavirus infection in men attending
    a sexually transmitted disease clinic. J Infect Dis 2003;
    187(7):1064-1070.

3.  Beutner KR, et al.  External Genital Warts: Report of the American
    Medical Association Consensus Conference.  Clin Inf Dis
    1998;27:796-806.

4.  Burk RD, et al. Sexual behavior and partner characteristics are the
    predominant risk factors for genital human papillomavirus infection
    in young women. J Infect Dis 1996; 174:679-689.

5.  Castellsague X, Bosch FX, Munoz N, Meijer CJ, Shah KV, de Sanjose S,
    et al. Male circumcision, penile human papillomavirus infection, and
    cervical cancer in female partners. N Engl J Med 2002;
    346(15):1105-1112.

6.  Castellsague X, Bosch FX, Munoz N. Environmental co-factors in HPV
    carcinogenesis. Virus Res 2002; 89(2):191-199.

7.  Castellsague X, Munoz N. Chapter 3: Cofactors in human
    papillomavirus carcinogenesis\--role of parity, oral contraceptives,
    and tobacco smoking. JNCI Monographs 2003;(31):20-28.

8.  Castle PE, Giuliano AR. Chapter 4: Genital tract infections,
    cervical inflammation, and antioxidant nutrients\--assessing their
    roles as human papillomavirus cofactors. JNCI Monographs
    2003;(31):29-34.

9.  Cates W, American Social Health Association Panel. Estimates of the
    incidence and prevalence of sexually transmitted diseases in the
    United States. Sex Transm Dis 1999; 26(suppl):52-57.

10. CDC. Sexually transmitted diseases treatment guidelines 2002. MMWR
    2002;51 (No. RR-6).  Available from URL:
    <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5106a1.htm>.

11. CDC. 1999 USPHS/IDSA guidelines for the prevention of opportunistic
    infections in persons infected with human immunodeficiency virus.
    MMWR 1999; 48:1-87.  Available from URL: 
    [http://www.cdc.gov/mmwr/preview/mmwrhtml/rr4810a1.htm.](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr4810a1.htm)

12. CDC. Prevention of genital HPV infection and sequelae: report of an
    external consultants\' meeting, 1999:1-33.  Available from URL:
    <http://www.cdc.gov/nchstp/dstd/Reports_Publications/99HPVReport.htm>.

13. Chang F, Syrjanen S, Kellokoski J, Syrjanen K. Human papillomavirus
    (HPV) infections and their associations with oral disease. J Oral
    Pathol Med 1991; 20(7):305-317.

14. Eddy DM. Screening for cervical cancer. Ann Int Med 1990;
    113(3):214-226.

15. Fairley CK, Chen S, Tabrizi SN, McNeil J, Becker G, Walker R, et al.
    Prevalence of HPV DNA in cervical specimens in women with renal
    transplants: a comparison with dialysis-dependent patients and
    patients with renal impairment. Nephrology Dialysis Transplantation
    1994; 9(4):416-420.

16. Ferenczy A, Bergeron C, Richart RM. Human papillomavirus DNA in
    fomites on objects used for the management of patients with genital
    human papillomavirus infections. Obstet Gynecol 1989; 74(6):950-954.

17. Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, Desy M, et
    al. Epidemiology of acquisition and clearance of cervical human
    papillomavirus infection in women from a high-risk area for cervical
    cancer. J Infect Dis 1999; 180(5):1415-1423.

18. Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Greer CE, Zhang T,
    et al. Persistence of type-specific human papillomavirus infection
    among cytologically normal women. J Infect Dis 1994; 169(2):235-240.

19. Hildesheim A, Herrero R, Castle PE, Wacholder S, Bratti MC, Sherman
    ME, et al. HPV co-factors related to the development of cervical
    cancer: results from a population-based study in Costa Rica. Br J
    Cancer 2001; 84(9):1219-1226.

20. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RDl.  Natural history
    of cervicovaginal papillomavirus infection in young women.  N Engl J
    Med 1998;338(7):423-428.

21. Ho GY, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, et al.
    Persistent genital human papillomavirus infection as a risk factor
    for persistent cervical dysplasia. JNCI 1995; 87(18):1365-1371.

22. Hogewoning CJ, Bleeker MC, Van den Brule AJ, Voorhorst FJ, Snijders
    PJ, Berkhof J, et al. Condom use promotes regression of cervical
    intraepithelial neoplasia and clearance of human papillomavirus: a
    randomized clinical trial. Int J Cancer 2003; (107) 811-816.

23. Holmes KK, Sparling PF, Mardh P-A, Lemon SM, Stamm WE, Piot P,
    Wasserheit JN (editors). Sexually transmitted diseases, 3rd ed. New
    York (NY): McGraw-Hill, 1999. Chapters 24, 25, 59, 86.

24. Jamieson DJ, Duerr A, Burk R, Klein RS, Paramsothy P, Schuman P, et
    al. Characterization of genital human papillomavirus infection in
    women who have or who are at risk of having HIV infection. Am J
    Obstet Gynecol 2002; 186(1):21-27.

25. Jenkins D. Diagnosing human papillomaviruses: recent advances. Curr
    Opin Infect Dis 2001; 14:53-56.

26. Karlsson R, Jonsson M, Edlund K, Evander M, Gustavsson A, Boden E,
    et al. Lifetime number of partners as the only independent risk
    factor for human papillomavirus infection: a population-based study.
    Sex Transm Dis 1995; 22(2):119-127.

27. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et
    al. A controlled trial of a human papillomavirus type 16
    vaccine.\[comment\]. NEJM 2002; 347(21):1645-1651.

28. Koutsky LA.  Epidemiology of genital human papillomavirus
    infection.  Am J Med 1997;102(5A):3-8.

29. Koutsky LA, Galloway DA, Holmes KK. Epidemiology of genital human
    papillomavirus infection. Epidemiol Rev 1988; 10:122-163.

30. Manhart LE, Koutsky LA. Do condoms prevent genital HPV infection,
    external genital warts, or cervical neoplasia? A meta-analysis. Sex
    Transm Dis 2002; 29(11):725-735.

31. Manos MM, et al.  Identifying women with cervical neoplasia.  JAMA
    1999; 281(17):1605-1610.

32. Molano M, Van den BA, Plummer M, Weiderpass E, Posso H, Arslan A, et
    al. Determinants of clearance of human papillomavirus infections in
    Colombian women with normal cytology: a population-based, 5-year
    follow-up study. Am J Epidemiol 2003; 158(5):486-494.

33. Moscicki AB, Hills N, Shiboski S, Powell K, Jay N, Hanson E, et al.
    Risks for incident human papillomavirus infection and low-grade
    squamous intraepithelial lesion development in young
    females.\[comment\]. JAMA 2001; 285(23):2995-3002.

34. Moscicki AB, Ellenberg JH, Vermund SH, Holland CA, Darragh T,
    Crowley-Nowick PA, et al. Prevalence of and risks for cervical human
    papillomavirus infection and squamous intraepithelial lesions in
    adolescent girls: impact of infection with human immunodeficiency
    virus. Arch Pediatr Adolesc Med 2000; 154(2):127-134.

35. Moscicki AB, Shiboski S, Broering J, Powell K, Clayton L, Jay N, et
    al. The natural history of human papillomavirus infection as
    measured by repeated DNA testing in adolescent and young women. J
    Pediatr 1998; 132(2):277-284.

36. Munoz N. Human papillomavirus and cancer: the epidemiological
    evidence. J Clin Virol 2000; 19(1-2):1-5.

37. Munoz N, Bosch FX. Epidemiology of cervical cancer. IARC Scientific
    Publications 1989;(94):9-39.

38. Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathematical
    model for the natural history of human papillomavirus infection and
    cervical carcinogenesis. Am J Epidemiol 2000; 151(12):1158-1171.

39. Ostor AG. Natural history of cervical intraepithelial neoplasia: a
    critical review. Int J Gynecol Pathol 1993; 12:186-92.

40. Peyton CL, Gravitt PE, Hunt WC, Hundley RS, Zhao M, Apple RJ, et al.
    Determinants of genital human papillomavirus detection in a US
    population. J Infect Dis 2001; 183(11):1554-1564.

41. Roden RB, Lowy DR, Schiller JT. Papillomavirus is resistant to
    desiccation. J Infect Dis 1997; 176(4):1076-1079.

42. Schiffman M, Kjaer SK. Chapter 2: Natural history of anogenital
    human papillomavirus infection and neoplasia. JNCI Monographs
    2003;(31):14-19.

43. Schlecht NF, Platt RW, Duarte-Franco E, Costa MC, Sobrinho JP, Prado
    JC, et al. Human papillomavirus infection and time to progression
    and regression of cervical intraepithelial neoplasia. JNCI 2003;
    95(17):1336-1343.

44. Sedjo RL, Fowler BM, Schneider A, Henning SM, Hatch K, Giuliano AR.
    Folate, vitamin B12, and homocysteine status findings of no relation
    between human papillomavirus persistence and cervical dysplasia.
    Nutrition 2003; 19(6):497-502.

45. Sith JS, Green J, Berrington dG, Appleby P, Peto J, Plummer M, et
    al. Cervical cancer and use of hormonal contraceptives: a systematic
    review. Lancet 2003; 361(9364):1159-1167.

46. Smith JS, Munoz N, Herrero R, Eluf-Neto J, Ngelangel C, Franceschi
    S, et al. Evidence for *Chlamydia trachomatis* as a human
    papillomavirus cofactor in the etiology of invasive cervical cancer
    in Brazil and the Philippines. J Infect Dis 2002; 185(3):324-331.

47. Solomon D, Schiffman M, Tarone R. Comparison of three management
    strategies for patients with atypical squamous cells of undetermined
    significance: baseline results from a randomized trial. JNCI 2001;
    93:293-299.

48. Solomon D, et al. The 2001 Bethesda System: Terminology for
    reporting results of cervical cytology.  JAMA 2002;
    287(16):2114-2119.

49. Svare EI, et al. Risk factors for HPV infection in women from
    sexually transmitted disease clinics:  comparison between two areas
    with different cervical cancer incidence. Int J Cancer 1998; 75:1-8.

50. U.S. Preventive Services Task Force. Screening for Cervical Cancer.
    AHRQ Publication No. 03-515A, 2003. Rockville (MD): Agency for
    Healthcare Research and Quality.  Available from URL:
    [http://www.ahrq.gov/clinic/3rduspstf/cervcan/cervcanrr.htm#contents.](http://www.ahrq.gov/clinic/3rduspstf/cervcan/cervcanrr.htm#contents)

51. von Krogh G, Lacey CJ, Gross G, Barrasso R, Schneider A. European
    course on HPV associated pathology: guidelines for primary care
    physicians for the diagnosis and management of anogenital warts. Sex
    Transm Infect 2000; 76:162-168.

52. Weinstock H. Berman S. Cates W Jr. Sexually transmitted diseases
    among American youth: incidence and prevalence estimates, 2000.
    Persp Sex Reprod Health 2004; 36(1), 6-10.

53. Wright TC, Cox JT, Massad LS, et al. 2001 Consensus guidelines for
    management of women with cervical cytological abnormalities. JAMA
    2002; 287(16): 2114-2129.

 

**Websites and Other Resources**

1.  CDC Division of STD Prevention: 
    [www.cdc.gov/std](http://www.cdc.gov/std)

2.  National Network of STD/HIV Prevention Training Centers: 
    <http://depts.washington.edu/nnptc/>

3.  2002 CDC STD Treatment Guidelines (including downloadable version
    for Palm devices):  <http://www.cdc.gov/STD/treatment/>

4.  CDC National STD Hotline:  800-227-8922 or 800-342-2437; En Español:
    800-344-7432; TTY for the Deaf and Hard of Hearing: 800-243-7889

5.  CDC National Prevention Information Network (NPIN): 
    [www.cdcnpin.org](http://www.cdcnpin.org/)

6.  American Social Health Association, National HPV and Cervical Cancer
    Prevention Resource Center: <http://www.ashastd.org/hpvccrc/>

7.  CDC Cervical Cancer and Pap Test Information
    <http://www.cdc.gov/cancer/nbccedp/info-cc.htm>

8.  National Cancer Institute (NCI):
    [http://www.nci.nih.gov](http://www.nci.nih.gov/)

9.  U.S. Preventive Services Task Force Cervical Cancer Screening
    Recommendations: <http://www.ahrq.gov/clinic/uspstf/uspscerv.htm>

10. American College of Obstetrics and Gynecology:
    [http://www.acog.org](http://www.acog.org/)

11. American Society of Colposcopy and Cervical Pathology (ASCCP):
    [http://www.asccp.org](http://www.asccp.org/)

[]{.mark}

[]{.mark}